The news is a tidal wave of catalysts! De-listing to OTC is a gut punch, but they're cleaning house and going all-in on their AI-driven Rx-to-OTC switch play. The tech is legit, aligning with new FDA rules for a $38B market. 📉 But the chart? Oof. The stock is getting crushed, trading way below its key averages with an RSI deep in oversold territory. This is pure, unadulterated speculation on a story stock. High-risk, high-reward punt. VERDICT: Speculative BUY for the brave. #BottomFisher

"Petros is cooking with gas! 🔥 Their AI-powered Rx-to-OTC pipeline just got a turbo boost from Trump’s executive order and big-data partnerships. The stock’s been crushed (RSI near 29—oversold alert!), but volume spikes hint at sneaky accumulation. WMAs are still bearishly stacked, but this feels like a coiled spring. If you’ve got nerves of steel, this is a speculative BUY before the FDA catalysts hit. #AIPharmaRevolution"

"Petros is firing on all cylinders! 🚀 With Trump’s Rx-to-OTC push, FDA wins, and AI collabs, this isn’t just hype—it’s a $38B market play. Technically? Oof, that RSI crash from 94 to 42 screams 'panic selloff,' but volume spiked on the dip—smart money loading up? WMAs are messy, but if news momentum holds, this could rebound hard. BUY the fear, but keep a tight stop. #BiotechBounce"